1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>China

Chinese Public Healthcare Insurance Official Defends Steep Drug Price Cuts

 
• By Dexter Jie Yan

China’s National Healthcare Security Administration (NHSA) seems determined to require pharma firms to comply with the agency’s request to cap the prices of innovative drugs, according to a senior official directly involved in annual price negotiations.

NHSA spending on novel drugs
China's NHSA expects drug makers to have a rough estimate of discounts needed for NRDL inclusion • Source: Shutterstock

In the run-up to China’s annual drug price talks, scheduled for November in an update to the National Reimbursement Drug List (NRDL), a senior official at the National Healthcare Security Administration (NHSA) made a rare public appearance to defend the agency’s tough price-cutting stance, which could dampen pharma companies’ hopes of negotiating a premium for their innovative drugs.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

China Approvals Rise But Conditional-To-Full Conversion Slips

 
• By Xu Hu

A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.

Elevar/Hengrui’s Second US CRL A Bad Omen For Multiregional Trials In Asia-Dominant Cancers?

 
• By Dexter Jie Yan

While CMC glitches linger over a US NDA for Elevar/Hengrui’s novel liver cancer combination following a second complete response letter, the separate issue of underrepresentation of US patients in multiregional trials is looming large after new FDA draft guidance last year.

China Signals Commercial Insurance, Biotech And Foreign-Owned Hospitals As Policy Priorities

 
• By Xu Hu

The main 2025 policy priorities for China's government as outlined in an annual report will include the strengthening of commercial insurance for innovative drugs and opening up cell and gene therapy and the hospital sector to foreign investment.

PhRMA Kicks Off Year Attacking China, Wrapping Agenda In American Flag

 
• By Sarah Karlin-Smith

US pharma leadership is painting its mission, particularly its goal to end Medicare price controls, as patriotic and essential to America’s global dominance over China, a move that seems designed to align with President Trump’s priorities.

More from Asia

Japan Pushes Generic Industry Reforms Via New Govt Fund

 
• By Lisa Takagi

Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.

Korea To Revise ‘Innovative Company’ Criteria Amid Calls From Foreign Industry

 
• By Jung Won Shin

South Korea announces planned revisions to a government scheme to designate "innovative" biopharma companies amid allegations of "discrimination" against foreign firms.

Combating Bioequivalence Data Fraud: Indian CROs Face Mandatory Registration

 
• By Urtė Fultinavičiūtė

As Indian CROs are bracing for new registration mandates, an expert panel at the IGBA’s 3rd Bioequivalence conference discusses the implications of non-compliance in bioequivalence studies.